The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Antiphospholipid Antibody Syndrome Puts Pregnant Women at High Risk of Preeclampsia

Antiphospholipid Antibody Syndrome Puts Pregnant Women at High Risk of Preeclampsia

June 20, 2016 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Olesia-Bilkei_shutterstock_Pregnancy_500x270Clinical practice guidelines recommend that women who are at high risk of pre-eclampsia should receive prophylactic aspirin beginning at 12–16 weeks of gestation. Unfortunately, physicians often have difficulty determining in early pregnancy which women are at high risk. Clinicians, thus, need an evidence-based list of risk factors that can be applied, before 16 weeks of gestation, to estimate a woman’s risk of developing pre-eclampsia. Researchers at the University of Toronto in Canada have now created such a list. They found that the strongest risk factor is the presence of antiphospholipid antibody syndrome.

You Might Also Like
  • Hope for Live Births in Women with Antiphospholipid Syndrome
  • Antiphospholipid Syndrome: The Risk of Travel at High Altitudes
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
Also By This Author
  • Study Points to Need for Increased Antirheumatic Therapy in Patients with Dyslipidemia

Emily Bartsch, BMSc, and colleagues published the results  of their systematic review on April 19 in BMJ.1 Their meta-analyses were designed to identify clinical risk factors that serve as potential determinants of preeclampsia.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“By restricting our analyses to studies examining risk factors determined in early pregnancy, we focused on risk factors that could lead to a timely intervention, such as aspirin prophylaxis,” write the authors in their discussion. “We generated reliable and consistent results across studies, as most were completed in the past two decades within Western countries, and about two-thirds used a standard clinical definition of pre-eclampsia. This was evidenced by a 2.7% weighted mean event rate for all risk factors across all unexposed groups, a figure close to that estimated within Western countries.”

The review identified 92 large sample cohort studies that included data from more than 25 million women. The investigators focused their efforts on determining the contributions of 14 common clinical risk factors for the development of preeclampsia. They calculated the pooled relative risk of developing preeclampsia in the presence or absence of each risk factor. They also calculated the pooled population attributable fraction for preeclampsia in relation to each risk factor. The large meta-analyses allowed them to avoid much of the bias that can be found in smaller studies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Five risk factors stood out as having the strongest association with a high rate of preeclampsia:

  • Antiphospholipid antibody syndrome (17.3%);
  • Chronic hypertension (16%);
  • Pregestational diabetes (11%);
  • Body mass index (BMI) > 30 (7.1%); and
  • Assisted reproductive technology (6.2%).

The presence of any one of these five risk factors translated into a woman being at high risk of developing preeclampsia. Although the presence of these risk factors may trigger use of prophylactic aspirin, the authors note that the effectiveness of aspirin in treating preeclampsia has not yet been evaluated for each individual risk factor or combination of risk factors. The authors suggest, however, that their list should allow clinicians to better estimate a woman’s risk of developing preeclampsia and, thus, better manage her care, whether it be by providing heightened surveillance or prophylactic aspirin.

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Antiphospholipid Antibody Syndrome (APS), Hughes Syndrome, preeclampsia, pregnancy, Risk Factors

You Might Also Like:
  • Hope for Live Births in Women with Antiphospholipid Syndrome
  • Antiphospholipid Syndrome: The Risk of Travel at High Altitudes
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • Why Antiphospholipid Antibody Syndrome Should Be On Your Radar

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)